Interpace Biosciences Inc.

01/09/2025 | Press release | Distributed by Public on 01/09/2025 17:13

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk